New hope for liver disease patients who Don't respond to standard treatment
NCT ID NCT07424677
Summary
This study is testing whether a medication called saroglitazar magnesium can help control primary biliary cholangitis, a chronic liver disease. The trial will involve 89 adults who either don't respond well to or can't tolerate the standard treatment. Participants will receive either the study drug or a placebo for 12 months to see if it normalizes their liver enzyme levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.